Health and Road Safety: Influence of Drugs Use and Health Status (CESIR-U2)
CESIR-U2 : Influence of Drugs Use and Health Status
In France, drugs affecting driving ability directly or by indicating at-risk diseases are classified in a 4-level standardized classification associated with a graded pictogram.
When the French authorities required this graded pictogram, they commissioned the CESIR-U1 study, a study designed to describe the use of labelled medicines by drivers involved in serious road accidents (hospitalization > 24h). This study, conducted in Bordeaux, Limoges and Toulouse, recruited 679 drivers involved in serious road accidents. When the responsibility of the driver is taken into account, it appears that the association of risk factors (alcohol, sleep, ...) and the use of labelled drugs increases this responsibility. Even though labelled medicines seemed slightly more at risk than unlabelled ones, this did not reach significance.
This conclusion is different from the conclusion of CESIR-A, a data linkage study of the police and the health insurance databases which showed a correlation between the use of grade 2 or 3 labelled medicines and driver responsibility.
This difference between CESIR-U and CESIR-A could be related to a lack of power or to the characteristics of the subjects included (mostly young men and motorcycle drivers). That is why it was thought interesting to increase the size of the sample and to include non serious road accidents (hospitalization < 24 hours) that represent around 73% of accidents.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
-
Bordeaux, Frankrig, 33000
- Hôpital Pellegrin
-
Périgueux, Frankrig
- CH de Périgueux
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Driver involved in a road accident and admitted in an emergency department
- Aged over 18 years
- Able to respond to a structured questionnaire
- Having agreed to participate in the study
Exclusion Criteria:
- Minors
- Passenger
- Pedestrian
- Discharge or transfer to another hospital/clinic before the interview
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: Kohorte
- Tidsperspektiver: Tværsnit
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
serious road accidents
Drivers involved in serious road accidents (hospitalization > 24 hours)
|
|
non-serious road accidents
drivers involved in non-serious road accidents (hospitalization < 24 hours).
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Drugs use reported by drivers involved in road accidents
Tidsramme: inclusion date
|
Drugs use is collected during a structured interview administered by a trained CRA.
Measure title : percentage of drivers who take drugs, by ATC classification, by pictogram and by drug.
|
inclusion date
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Responsibility of the driver for the accident
Tidsramme: inclusion date
|
The responsibility of the driver (responsible or not responsible) is a data extracted from the BAAC sheet (a sheet fulfilled by the police in case of traffic crashes)
|
inclusion date
|
|
Seriousness of the accident
Tidsramme: inclusion date
|
The seriousness of the accident is assessed according the duration of hospital stay.
If the duration is less than 24 hours, accidents are considered as non serious.
If not, accidents are considered as serious.
|
inclusion date
|
|
Knowledge of drivers about graded pictogram featured on drugs packaging
Tidsramme: inclusion date
|
Knowledge about graded pictogram is collected during a structured interview administered by a trained CRA.
Measure title : percentage of drivers who know if a pictogram is featured on their drugs packagings.
|
inclusion date
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studiestol: Nicholas MOORE, Pr, Plateforme BPE
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- CHUBX 2012/33
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Bilulykke
-
Xuzhou Medical UniversityIkke rekrutterer endnuIkke-invasiv CAR-T-celleovervågning | BCMA-målrettet PET-skanning | CAR-T-cellebiodistribution og -persistens | GMP-overensstemmende Radiopharmaka-præparation
-
The Affiliated Hospital of Xuzhou Medical UniversityRekrutteringCLL | SLL | CAR-T celleterapiKina
-
Duke UniversityNational Institutes of Health (NIH)RekrutteringHæmatopoietisk stamcelletransplantation | CAR-T celleterapiForenede Stater
-
Patrick C. Johnson, MDRekruttering
-
Stiftung Swiss Tumor InstituteKlinik Hirslanden, Zurich; Palleos Healthcare GmbHRekrutteringPatientrapporterede resultatmål | CAR T-celleterapiSchweiz
-
University Health Network, TorontoIkke rekrutterer endnuLymfom, der modtager CAR-T-terapiCanada
-
The Lymphoma Academic Research OrganisationBristol-Myers Squibb; Novartis; Gilead SciencesRekrutteringHæmatopatologi kvalificeret eller CAR-t-cellebehandlingFrankrig
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRekrutteringCAR-T Terapi KomplikationerItalien
-
Henan Cancer HospitalFundamenta Therapeutics, Ltd.Ikke rekrutterer endnuAllogen, CAR-T, proteinsekvestrering, ikke-genredigeretKina
-
Shanghai International Medical CenterUkendtAvanceret solid tumor | PD-1 antistof | CAR-T cellerKina